Printer Friendly

BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK

 PORTLAND, Ore., April 20 /PRNewswire/ -- Bioject Inc., a subsidiary of Bioject Medical Technologies Inc. (NASDAQ: BJCT), today announced the expansion of its national product distribution after signing agreements with the Alliance Group, a national network of 12 medical specialty distributors, and two California-based specialty distributors, Med Spec Inc. and San Jose Surgical.
 These new sales centers will cover the U.S. coast-to-coast and focus on expanding Bioject's presence by utilizing the increased number of sales representatives provided by the agreements. Bioject's new distribution partners will be coordinated by the company's five area sales managers who began sale efforts of the Biojector(R) 2000 on January 25 of this year.
 "We are very excited about the addition of this very elite group to our sales team," commented Carl E. Wilcox, Bioject's president and CEO. "There will now be more than 130 sales representatives calling on hospitals and large clinics on behalf of the Biojector 2000 needle-free injection mRichard Hollis, Bioject's chief operating officer. "Our target was at least 70 distribution reps. This clearly exceeds our expectations and is a vote of confidence for Bioject's product. These distributors have a very successful record of bringing new medical products to market," Hollis added.
 In addition to the new distribution arrangement, the company also has a joint development agreement with Eli Lilly and Company for the development of an injection management system for the home healthcare market. Product distribution in Japan is also anticipated to begin later this year under Bioject's agreement with Kobayashi Pharmaceutical Co., Ltd.
 Bioject is an Oregon corporation dedicated to developing and marketing advanced drug delivery systems using needle-free injection technology. Its products dramatically reduce or eliminate the risk of life-threatening needlestick injuries to healthcare workers and their patients that could result in the transmission of bloodborne pathogens (including hepatitis B and AIDS).
 -0- 4/20/93 R
 /CONTACT: Dan Zenka, APR, or Tim Justice, both of Bioject Inc., 503-639-7221/
 (BJCT)


CO: Bioject Inc.; Bioject Medical Technologies Inc. ST: Oregon IN: HEA SU:

TM -- SE007 -- 8667 04/21/93 11:11 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1993
Words:342
Previous Article:Z/COM WINS PROMOTIONAL POINT-OF-PURCHASE CAMPAIGN FOR LEADING EDGE TELECOMMUNICATIONS COMPANY
Next Article:KANSAS CITY POWER & LIGHT REDEEMS FIRST MORTGAGE BONDS
Topics:


Related Articles
BIOJECT OPENS SOUTHWEST SALES REGION FOR NEEDLE-FREE INJECTOR
BIOJECT EXPANDS PRODUCT DISTRIBUTION WITH NATIONAL NETWORK
BIOJECT EXPANDS PHYSICIAN OFFICE DISTRIBUTION WITH TAYLOR MEDICAL
BIOJECT ANNOUNCES INCREASED REVENUES FOR SECOND QUARTER, FISCAL 1994; NASDAQ NATIONAL MARKET SYSTEM LISTING
BIOJECT ANNOUNCES RESULTS FOR THIRD QUARTER FISCAL 1994
BIOJECT SIGNS PURCHASING AGREEMENT WITH PREMIER HEALTH ALLIANCE INC.
BIOJECT SIGNS DEVELOPMENT AGREEMENT WITH HOFFMANN-LA ROCHE
BIOJECT AND SCHERING AG, GERMANY, SIGN SUPPLY AGREEMENT FOR BETASERON(R) INJECTION SYSTEMS
Bioject Announces Cancellation of Contract With Schering AG
Bioject Expands Contract With the Centers for Disease Control for Global Immunization Device.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters